Based on the key indicators related to AN2 Therapeutics' liquidity, profitability, solvency, and operating efficiency, AN2 Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, AN2 Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Other Stockholder Equity is likely to rise to about 336.7 M in 2025, whereas Net Debt is likely to drop (14.8 M) in 2025. Key indicators impacting AN2 Therapeutics' financial strength include:
Investors should never underestimate AN2 Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor AN2 Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in AN2 Therapeutics.
Net Income
(55.35 Million)
AN2
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Cash Ratio
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Stock Based Compensation
Begin Period Cash Flow
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Total Liab
Total Current Assets
Non Current Assets Total
Short Term Investments
Other Stockholder Equity
Net Invested Capital
Long Term Investments
Net Working Capital
Non Currrent Assets Other
Other Assets
Accumulated Other Comprehensive Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Interest Income
Net Income From Continuing Ops
Probability Of Bankruptcy
Understanding current and past AN2 Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AN2 Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in AN2 Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in AN2 Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AN2 Therapeutics. Check AN2 Therapeutics' Beneish M Score to see the likelihood of AN2 Therapeutics' management manipulating its earnings.
AN2 Therapeutics Stock Summary
AN2 Therapeutics competes with Aerovate Therapeutics, Adagene, Acrivon Therapeutics,, Rezolute, and Anebulo Pharmaceuticals. AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California. An2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Comparative valuation techniques use various fundamental indicators to help in determining AN2 Therapeutics's current stock value. Our valuation model uses many indicators to compare AN2 Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AN2 Therapeutics competition to find correlations between indicators driving AN2 Therapeutics's intrinsic value. More Info.
AN2 Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, AN2 Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AN2 Therapeutics' earnings, one of the primary drivers of an investment's value.
AN2 Therapeutics Systematic Risk
AN2 Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AN2 Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on AN2 Therapeutics correlated with the market. If Beta is less than 0 AN2 Therapeutics generally moves in the opposite direction as compared to the market. If AN2 Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AN2 Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AN2 Therapeutics is generally in the same direction as the market. If Beta > 1 AN2 Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
AN2 Therapeutics Thematic Clasifications
AN2 Therapeutics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in AN2 Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AN2 Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of AN2 Therapeutics growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of AN2 Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AN2 Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of AN2 Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing AN2 Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AN2 Therapeutics's daily price indicators and compare them against related drivers.
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.